Two Sigma Investments LP raised its place in Editas Medication, Inc. (NASDAQ:EDIT) by 52.6% within the third quarter, in line with its most up-to-date submitting with the SEC. The agency owned 378,115 shares of the corporate’s inventory after buying an extra 130,394 shares throughout the interval. Two Sigma Investments LP’s holdings in Editas Medication had been price $15,533,000 on the finish of the newest reporting interval.
Different hedge funds have additionally not too long ago added to or decreased their stakes within the firm. CKW Monetary Group acquired a brand new stake in shares of Editas Medication within the third quarter price $28,000. Advisory Providers Community LLC acquired a brand new stake in shares of Editas Medication within the second quarter valued at about $32,000. Manchester Capital Administration LLC acquired a brand new stake in shares of Editas Medication within the third quarter valued at about $82,000. Macquarie Group Ltd. lifted its stake in shares of Editas Medication by 19.7% within the second quarter. Macquarie Group Ltd. now owns 1,957 shares of the corporate’s inventory valued at $111,000 after buying an extra 322 shares throughout the interval. Lastly, Complete Readability Wealth Administration Inc. acquired a brand new stake in shares of Editas Medication within the third quarter valued at about $115,000. Institutional buyers personal 67.71% of the corporate’s inventory.
In associated information, CFO Michelle Robertson offered 1,744 shares of the enterprise’s inventory in a transaction that occurred on Tuesday, January eleventh. The shares had been offered at a median worth of $25.70, for a complete worth of $44,820.80. The transaction was disclosed in a submitting with the Securities & Change Fee, which is accessible via this hyperlink. 0.94% of the inventory is at present owned by insiders.
A number of brokerages not too long ago commented on EDIT. Zacks Funding Analysis upgraded shares of Editas Medication from a “maintain” score to a “purchase” score and set a $20.00 worth goal for the corporate in a analysis word on Thursday, February third. Morgan Stanley minimize their goal worth on shares of Editas Medication from $37.00 to $24.00 and set an “underweight” score for the corporate in a analysis report on Thursday, January sixth. Lastly, Evercore ISI minimize shares of Editas Medication to a “maintain” score and set a $15.00 goal worth for the corporate. in a analysis report on Friday, February eleventh. Three analysis analysts have rated the inventory with a promote score, 5 have assigned a maintain score and 6 have given a purchase score to the corporate’s inventory. Primarily based on knowledge from MarketBeat, Editas Medication at present has a median score of “Maintain” and a consensus goal worth of $44.23.
Shares of NASDAQ EDIT opened at $15.20 on Tuesday. The corporate has a market cap of $1.04 billion, a PE ratio of -4.69 and a beta of two.03. Editas Medication, Inc. has a 12 month low of $15.03 and a 12 month excessive of $73.03. The corporate has a 50-day easy transferring common of $22.32 and a 200-day easy transferring common of $38.26.
Editas Medication Profile
Editas Medication, Inc engages within the improvement and commercialization of genome modifying expertise. Its expertise consists of clustered, repeatedly interspaced brief palindromic repeats (CRISPR), and CRISPR related protein 9 (Cas9). The corporate was based by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J.
Need to see what different hedge funds are holding EDIT? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Editas Medication, Inc. (NASDAQ:EDIT).
Need Extra Nice Investing Concepts?